Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Lenz

Showing results (271-280 of 294) with videos related to

Pageof 30
Sort By:
Blood Advances|October 22, 2025
Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell EngagersGiulia Magno, Kai Rejeski, Giulia Rappa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisoneNathalie A Johnson, Graham W Slack, Kerry J Savage, et al.
Blood Advances|July 1, 2021
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomasNora Liebers, Johannes Duell, Donnacha Fitzgerald, et al.
Leukemia|June 12, 2019
The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemiaLinus Angenendt, Eike Bormann, Caroline Pabst, et al.
Nature Cancer|March 26, 2026
Reprogramming of stroma-derived chemokine networks drives the loss of tissue organization in nodal B cell lymphomaFelix Czernilofsky, Anna Mathioudaki, Lea Jopp-Saile, et al.
Blood Advances|April 16, 2025
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphomaEvgenii Shumilov, Julia Katharina Scholz, Maximilian Seib, et al.
Blood Advances|December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World StudyEvgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2024
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)Olivier Tournilhac, Bettina Altmann, Birte Friedrichs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2025
Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell LymphomaFranck Morschhauser, Gilles Salles, Laurie H Sehn, et al.
Cancer Cell|December 16, 2010
Cooperative epigenetic modulation by cancer amplicon genesLixin Rui, N C Tolga Emre, Michael J Kruhlak, et al.
Pageof 30

Showing results (271-280 of 294) with videos related to

Sort By:
Pageof 30
Blood Advances|October 22, 2025
Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell EngagersGiulia Magno, Kai Rejeski, Giulia Rappa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisoneNathalie A Johnson, Graham W Slack, Kerry J Savage, et al.
Blood Advances|July 1, 2021
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomasNora Liebers, Johannes Duell, Donnacha Fitzgerald, et al.
Leukemia|June 12, 2019
The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemiaLinus Angenendt, Eike Bormann, Caroline Pabst, et al.
Nature Cancer|March 26, 2026
Reprogramming of stroma-derived chemokine networks drives the loss of tissue organization in nodal B cell lymphomaFelix Czernilofsky, Anna Mathioudaki, Lea Jopp-Saile, et al.
Blood Advances|April 16, 2025
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphomaEvgenii Shumilov, Julia Katharina Scholz, Maximilian Seib, et al.
Blood Advances|December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World StudyEvgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2024
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)Olivier Tournilhac, Bettina Altmann, Birte Friedrichs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2025
Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell LymphomaFranck Morschhauser, Gilles Salles, Laurie H Sehn, et al.
Cancer Cell|December 16, 2010
Cooperative epigenetic modulation by cancer amplicon genesLixin Rui, N C Tolga Emre, Michael J Kruhlak, et al.
Pageof 30